Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 1 Liver Neoplasms 1 Liver Diseases 1 Hepatitis C 1

Interventions

Ribavirin 4 ledipasvir, sofosbuvir drug combination 2 Chromatography, High Pressure Liquid 2 tremelimumab 1 telaprevir 1 sofosbuvir-velpatasvir drug combination 1 pembrolizumab 1 peginterferon alfa-2a 1 ledipasvir 1 grazoprevir 1 elbasvir-grazoprevir drug combination 1 elbasvir 1 Sofosbuvir 1 Rapid Diagnostic Tests 1 Patient Navigation 1 Introns 1 Infliximab 1 Immunoenzyme Techniques 1 Hypothermia, Induced 1 Enzyme-Linked Immunosorbent Assay 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Hepatitis C × Sofosbuvir × Clear all

NCT02717949 2019-01-08

Optimal

University of Texas Southwestern Medical Center

Phase 4 Terminated

Hepatitis C, Liver Diseases, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡